Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms.
Fontanelli G, Baratè C, Ciabatti E, Guerrini F, Grassi S, Del Re M, Morganti R, Petrini I, Arici R, Barsotti S, Metelli MR, Danesi R, Galimberti S. Fontanelli G, et al. Among authors: petrini i. Int J Lab Hematol. 2015 Dec;37(6):766-73. doi: 10.1111/ijlh.12404. Epub 2015 Jul 20. Int J Lab Hematol. 2015. PMID: 26189968
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.
Del Re M, Tiseo M, Bordi P, D'Incecco A, Camerini A, Petrini I, Lucchesi M, Inno A, Spada D, Vasile E, Citi V, Malpeli G, Testa E, Gori S, Falcone A, Amoroso D, Chella A, Cappuzzo F, Ardizzoni A, Scarpa A, Danesi R. Del Re M, et al. Among authors: petrini i. Oncotarget. 2017 Feb 21;8(8):13611-13619. doi: 10.18632/oncotarget.6957. Oncotarget. 2017. PMID: 26799287 Free PMC article.
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia.
Guerrini F, Paolicchi M, Ghio F, Ciabatti E, Grassi S, Salehzadeh S, Ercolano G, Metelli MR, Del Re M, Iovino L, Petrini I, Carulli G, Cecconi N, Rousseau M, Cervetti G, Galimberti S. Guerrini F, et al. Among authors: petrini i. Front Pharmacol. 2016 Oct 13;7:363. doi: 10.3389/fphar.2016.00363. eCollection 2016. Front Pharmacol. 2016. PMID: 27790140 Free PMC article.
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.
Del Re M, Bordi P, Petrini I, Rofi E, Mazzoni F, Belluomini L, Vasile E, Restante G, Di Costanzo F, Falcone A, Frassoldati A, van Schaik RHN, Steendam CMJ, Chella A, Tiseo M, Morganti R, Danesi R. Del Re M, et al. Among authors: petrini i. Oncotarget. 2017 Sep 15;8(49):86056-86065. doi: 10.18632/oncotarget.20947. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156777 Free PMC article.
Implications of KRAS mutations in acquired resistance to treatment in NSCLC.
Del Re M, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S, Di Maio M, Petrini I, Danesi R. Del Re M, et al. Among authors: petrini i. Oncotarget. 2017 Dec 21;9(5):6630-6643. doi: 10.18632/oncotarget.23553. eCollection 2018 Jan 19. Oncotarget. 2017. PMID: 29464099 Free PMC article. Review.
93 results